Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin…
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin…
The new Busch and Pfeiffer Vacuum building became necessary due to the positive business development of the Busch Group…
BSI Life Sciences announces it has been awarded a SaaS agreement by global contract research organization HEMEX to provi…
Implenia’s Division Buildings has won construction contracts in various regions of Switzerland and Germany worth a total…
RELUX is integrating the real-time rendering engine from Chaos Enscape in its latest release – ReluxDesktop 2024.1. The…
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CH…
Third-quarter revenue amounts to CHF 571 million, an increase of 11% organic growth, bringing revenue in the first n…
The Frankfurt-based E3 WORLD Group, the 360-degree provider for exhibitions, events and environments, today introduces i…
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 3…
. New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31,…